REGENERON PHARMACEUTICALS, INC. (REGN) revenue & profit
REGENERON PHARMACEUTICALS, INC. (REGN): revenue $14.3B, net income $4.5B in 2025; latest quarter +16.7% year over year. From SEC filings.
$14.3BRevenue 2025
TickerREGN (Nasdaq)
IndustryHealthcare · Pharmaceutical Preparations
Revenue 2025$14.3B
Net income 2025$4.5B
Net margin31.4%
Annual revenue growth+1%
Latest quarter (2026 Q2) · Revenue$4.3B
vs. same quarter last year+16.7%
Latest quarter · Net income$1.3B
Annual revenue & net income
| Year | Revenue | Net income | |
|---|---|---|---|
| 2022 | $12.2B | $4.3B | |
| 2023 | $13.1B | $4B | |
| 2024 | $14.2B | $4.4B | |
| 2025 | $14.3B | $4.5B |
ℹ️ Not investment advice. Calendar-year figures as tagged by the SEC; a company’s fiscal year may end in a different month.